Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Liabilities and Shareholders Equity (2023 - 2025)

Compass Therapeutics' Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $219.6 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 56.4% year-over-year to $219.6 million; the TTM value through Dec 2025 reached $699.0 million, up 15.29%, while the annual FY2025 figure was $219.6 million, 56.4% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $219.6 million at Compass Therapeutics, down from $231.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $231.3 million in Q3 2025 and bottomed at $116.7 million in Q2 2025.
  • The 3-year median for Liabilities and Shareholders Equity is $159.0 million (2023), against an average of $166.6 million.
  • The largest YoY upside for Liabilities and Shareholders Equity was 56.4% in 2025 against a maximum downside of 25.01% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $156.9 million in 2023, then dropped by 10.5% to $140.4 million in 2024, then skyrocketed by 56.4% to $219.6 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Liabilities and Shareholders Equity are $219.6 million (Q4 2025), $231.3 million (Q3 2025), and $116.7 million (Q2 2025).